156 related articles for article (PubMed ID: 26791869)
1. Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy.
Marachelian A; Desai A; Balis F; Katzenstein H; Qayed M; Armstrong M; Neville KA; Cohn SL; Bush M; Gunawan R; Lim AP; Smith MA; Smith LM
Cancer Chemother Pharmacol; 2016 Feb; 77(2):405-12. PubMed ID: 26791869
[TBL] [Abstract][Full Text] [Related]
2. Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study.
Ladenstein R; Weixler S; Baykan B; Bleeke M; Kunert R; Katinger D; Pribill I; Glander P; Bauer S; Pistoia V; Michon J; Garaventa A; Lode HN
MAbs; 2013; 5(5):801-9. PubMed ID: 23924804
[TBL] [Abstract][Full Text] [Related]
3. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K; Bernhardt B; Strickland B
Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
[TBL] [Abstract][Full Text] [Related]
4. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD
Mueller I; Ehlert K; Endres S; Pill L; Siebert N; Kietz S; Brock P; Garaventa A; Valteau-Couanet D; Janzek E; Hosten N; Zinke A; Barthlen W; Varol E; Loibner H; Ladenstein R; Lode HN
MAbs; 2018 Jan; 10(1):55-61. PubMed ID: 29120699
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma.
Desai AV; Fox E; Smith LM; Lim AP; Maris JM; Balis FM
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1047-55. PubMed ID: 25212536
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory response and treatment tolerance of long-term infusion of the anti-GD
Ceylan K; Jahns LJ; Lode BN; Ehlert K; Kietz S; Troschke-Meurer S; Siebert N; Lode HN
Pediatr Blood Cancer; 2018 Jun; 65(6):e26967. PubMed ID: 29350486
[TBL] [Abstract][Full Text] [Related]
7. Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab.
Siebert N; Seidel D; Eger C; Brackrock D; Reker D; Schmidt M; Lode HN
J Immunol Methods; 2013 Dec; 398-399():51-9. PubMed ID: 24055592
[TBL] [Abstract][Full Text] [Related]
8. Dinutuximab: first global approval.
Dhillon S
Drugs; 2015 May; 75(8):923-7. PubMed ID: 25940913
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2.
Siebert N; Eger C; Seidel D; Jüttner M; Zumpe M; Wegner D; Kietz S; Ehlert K; Veal GJ; Siegmund W; Weiss M; Loibner H; Ladenstein R; Lode HN
MAbs; 2016; 8(3):604-16. PubMed ID: 26785755
[TBL] [Abstract][Full Text] [Related]
10. Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy.
Terzic T; Cordeau M; Herblot S; Teira P; Cournoyer S; Beaunoyer M; Peuchmaur M; Duval M; Sartelet H
Pediatr Dev Pathol; 2018; 21(4):355-362. PubMed ID: 29067879
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study.
Ozkaynak MF; Sondel PM; Krailo MD; Gan J; Javorsky B; Reisfeld RA; Matthay KK; Reaman GH; Seeger RC
J Clin Oncol; 2000 Dec; 18(24):4077-85. PubMed ID: 11118469
[TBL] [Abstract][Full Text] [Related]
12. The safety of dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
Greenwood KL; Foster JH
Expert Opin Drug Saf; 2018 Dec; 17(12):1257-1262. PubMed ID: 30433831
[TBL] [Abstract][Full Text] [Related]
13. Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.
Seitz CM; Flaadt T; Mezger M; Lang AM; Michaelis S; Katz M; Syring D; Joechner A; Rabsteyn A; Siebert N; Troschke-Meurer S; Zumpe M; Lode HN; Yang SF; Atar D; Mast AS; Scheuermann S; Heubach F; Handgretinger R; Lang P; Schlegel P
Front Immunol; 2021; 12():690467. PubMed ID: 34367149
[TBL] [Abstract][Full Text] [Related]
14. Dinutuximab for maintenance therapy in pediatric neuroblastoma.
McGinty L; Kolesar J
Am J Health Syst Pharm; 2017 Apr; 74(8):563-567. PubMed ID: 28389455
[TBL] [Abstract][Full Text] [Related]
15. Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: A case series.
Ding YY; Panzer J; Maris JM; Castañeda A; Gomez-Chiari M; Mora J
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28748630
[TBL] [Abstract][Full Text] [Related]
16. Dinutuximab for the treatment of pediatric patients with neuroblastoma.
Greenwood K; Foster JH
Drugs Today (Barc); 2017 Sep; 53(9):469-476. PubMed ID: 29238760
[TBL] [Abstract][Full Text] [Related]
17. Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
Mora J
Expert Rev Clin Pharmacol; 2016; 9(5):647-53. PubMed ID: 26934530
[TBL] [Abstract][Full Text] [Related]
18. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
Yu AL; Gilman AL; Ozkaynak MF; London WB; Kreissman SG; Chen HX; Smith M; Anderson B; Villablanca JG; Matthay KK; Shimada H; Grupp SA; Seeger R; Reynolds CP; Buxton A; Reisfeld RA; Gillies SD; Cohn SL; Maris JM; Sondel PM;
N Engl J Med; 2010 Sep; 363(14):1324-34. PubMed ID: 20879881
[TBL] [Abstract][Full Text] [Related]
19. Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma.
Ploessl C; Pan A; Maples KT; Lowe DK
Ann Pharmacother; 2016 May; 50(5):416-22. PubMed ID: 26917818
[TBL] [Abstract][Full Text] [Related]
20. Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma.
Anghelescu DL; Goldberg JL; Faughnan LG; Wu J; Mao S; Furman WL; Santana VM; Navid F
Pediatr Blood Cancer; 2015 Feb; 62(2):224-228. PubMed ID: 25382742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]